You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 5, May 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Is Surgery Necessary in Stage III and Stage IV Cancer of the Head and Neck That Responds to Induction Chemotherapy?

Michael Poulsen, FRACR; Chris Aldren, FRCS; Lee Tripcony, BSc; Quenten Walker, FRACR

Arch Otolaryngol Head Neck Surg. 1996;122(5):467-471.


Abstract

Objective
To study the influence of surgery in patients who achieve a response to induction chemotherapy.

Design
Nonrandomized retrospective study.

Setting
Comprehensive cancer center.

Patients
The records of all patients with stage III and stage IV squamous cell carcinoma of the oral cavity, oropharynx, and hypopharynx were reviewed at the Queensland Radium Institute, South Brisbane, Australia, in the years 1970 through 1990.

Interventions
There were 314 patients where induction chemotherapy was used as part of a curative treatment. Complete response occurred in 20 patients, partial response in 110 patients, nonresponse in 162 patients, and unknown response in 22 patients. To assess the impact of surgery, the responders were divided into two treatment groups: one group (n=57) received chemotherapy, surgery, and radiotherapy (C/S/XRT), and a second group (n=73) received chemotherapy and radiotherapy (C/XRT).

Main Outcome Measures
Five-year survival, local failure, nodal failure, and distant failure.

Results
The 5-year actuarial survival for the chemotherapy responders and nonresponders was 58% and 43%, respectively (P<.05). When analyzed by treatment group, those receiving C/S/XRT had a 65% 5-year survival (95% confidence intervals [CIs], 53 to 78) and those receiving C/XRT had a 56% 5-year survival (95% CI, 44 to 70). However, when the complete responders were assessed, those receiving C/S/XRT had a 90% 5-year survival (95% CI, 72 to 99) vs a 51% survival (95% CI, 18 to 89) for those treated with C/XRT. For the partial responders, the survival for the groups C/S/XRT and C/XRT were 59% (95% CI, 45 to 79) and 53% (95% CI, 41 to 67), respectively. Chemotherapy responders were less likely to fail locally if they were treated with C/S/XRT than with C/XRT (21% vs 43%, P<.01).

Conclusion
The results suggest that surgery still has a role to play in patients who achieve a response with chemotherapy, even when the response is complete.

(Arch Otolaryngol Head Neck Surg. 1996;122:467-471)



Author Affiliations

From the Mater Center, Queensland Radium Institute (Drs Poulsen, Walker, and Tripcony), and the Department of Ear, Nose, and Throat, Princess Alexandra Hospital (Dr Tripcony), South Brisbane, Australia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intra-Arterial High-Dose Chemotherapy with Cisplatin as Part of a Palliative Treatment Concept in Oral Cancer
Rohde et al.
Am. J. Neuroradiol. 2005;26:1804-1809.
ABSTRACT | FULL TEXT  

Combined Modality Treatment of Advanced Head and Neck Cancer
Lawrence and Bansal
Arch Otolaryngol Head Neck Surg 1997;123:116-116.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.